Volition's nu.q® vet cancer test now available for pre-order at the point-of-care through heska corporation

Henderson, nev., feb. 16, 2023 /prnewswire/ -- volitionrx limited (nyse american: vnrx) ("volition"), a multi-national epigenetics company, announces its nu.q® vet cancer test is now available for pre-order to veterinarians at the point-of-care through heska corporation (nasdaq: hska) ("heska").

VNRX Ratings Summary

VNRX Quant Ranking